Please login to the form below
oxaliplatin
This page shows the latest oxaliplatin news and features for those working in and with pharma, biotech and healthcare.
FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer
In this trial, the Keytruda/Herceptin treatment regimen plus either 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin demonstrated a statistically significant objective response rate (ORR) of 74%, compared with 52%
Latest news
-
Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial
In the SEQUOIA trial, pegilodecakin was added to the widely-used FOLFOX regimen (folinic acid, 5-fluorouracil and oxaliplatin) as second-line therapy for metastatic pancreatic cancer patients who had progressed
-
Celgene’s Abraxane fails pancreatic cancer trial
Since APACT was started, a new regimen called mFOLFIRINOX – based on oxaliplatin, leucovorin, irinotecan, and fluorouracil – has been shown to be more effective gemcitabine in adjuvant pancreatic cancer.
-
Innovent gears up for PD-1 inhibitor launch in China
Last month it started a phase 3 study of Tyvyt in in combination with capecitabine and oxaliplatin, as first-line treatment for patients with advanced, recurrent or metastatic gastric or gastroesophageal
-
Chi-Med and Lilly’s cancer drug Elunate a milestone for China
Elunate is approved for treatment of patients with metastatic colorectal cancer (CRC) previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received or are unsuitable for VEGF therapy
-
NICE knocks-back Shire's pancreatic cancer drug Onivyde
Noting that established NHS clinical practice in this setting is actually for oxaliplatin plus 5-FU and LV, NICE also considered this and found Onivyde with 5-FU and LV has
More from news
Approximately 0 fully matching, plus 38 partially matching documents found.
Latest appointments
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
oxaliplatin) for colon cancer.
-
Former Bayer oncology head Robert Rosen joins AP Pharma's board
Prior to his time at Bayer, Rosen spent three years at Sanofi-Synthelabo as VP of its oncology business unit, and was responsobile for the launch of Eloxatin (oxaliplatin) for colon
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- The importance of beliefs in creative health engagement
- In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Almirall shares positive topline results from atopic dermatitis trials
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
